Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Cancellation can be done through the patient portal, by email, or by phone
Gehrig SM, van der Poel C, Hoeflich A, et al
Table of Contents Understanding the GLP-1 market landscape Navigating safety and regulatory scrutiny Differentiation in a saturated market Building trust through patient-centered messaging Understanding the Evolving GLP-1 Market Landscape The GLP-1 category has grown rapidly, driven by demand for weight management and diabetes care
We encourage every client to use Semaglutide as a partner in their journey, not the entire plan
As part of the prior authorization process for Bridge, prescribing clinicians will need to attest that the GLP-1 prescription is for weight reduction and weight management and that beneficiaries meet the clinical criteria and do not have a diagnosis of type 2 diabetes, OSA, or MASH that would make them eligible for GLP-1 coverage under Part D
